文献速递流行病学与生物统计临床试验与 GCP

结直肠癌筛查:美国预防服务工作组更新证据报告与系统综述

Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2021-01-01

该系统综述评估了结直肠癌筛查的有效性、检测准确性和危害,纳入33项有效性研究、59项检测性能研究和131项危害研究。随机试验显示,乙状结肠镜筛查与结直肠癌特异性死亡率降低相关(IRR 0.74,95%CI 0.68-0.80),愈创木脂粪便隐血试验(gFOBT)筛查也降低死亡率。多种筛查方案各有不同的证据水平、检测能力和危害风险。

要点

  • 乙状结肠镜筛查与结直肠癌死亡率降低相关(IRR 0.74)。
  • gFOBT筛查在19.5年和30年随访时均降低结直肠癌死亡率。
  • 结肠镜筛查的严重危害包括穿孔(3.1/10 000)和大出血(14.6/10 000)。

核心结论

  • 有多种结直肠癌筛查方案可选,每种方案在降低癌症死亡率、检测癌症或癌前病变的能力以及危害风险方面的证据水平不同。

研究设计与样本

  • 系统综述纳入33项有效性研究(n=10 776 276)、59项检测性能研究(n=3 491 045)和131项危害研究(n=26 987 366)。
  • 检索MEDLINE、PubMed和Cochrane Central Register of Controlled Trials,纳入2015年1月1日至2019年12月4日发表的研究,监测至2021年3月26日。
  • 纳入无症状一般风险人群的英文研究,由两名评价者独立评估并提取 fair 或 good 质量研究的数据,进行随机效应meta分析。

主要发现

  • 4项随机试验(n=458 002)中,意向筛查接受1次或2次乙状结肠镜 vs 不筛查与结直肠癌特异性死亡率降低相关(IRR 0.74,95%CI 0.68-0.80)。
  • 5项随机试验(n=419 966)中,每年或每两年gFOBT筛查 vs 不筛查在2至9轮筛查后与结直肠癌特异性死亡率降低相关(19.5年RR 0.91,95%CI 0.84-0.98;30年RR 0.78,95%CI 0.65-0.93)。
  • 汇总分析中,常用FIT(14项研究,n=45 403)检测癌症的敏感性为0.74、特异性为0.94;粪便DNA联合FIT(4项研究,n=12 424)敏感性为0.93、特异性为0.85;高灵敏度gFOBT(2项研究,n=3503)敏感性为0.50-0.75、特异性为0.96-0.98。
  • CT结肠成像(需肠道准备)检测≥6 mm腺瘤的汇总敏感性为0.86,结肠镜为0.89。

关键数值与推荐

  • 乙状结肠镜筛查 vs 不筛查:结直肠癌特异性死亡率IRR 0.74(95%CI 0.68-0.80)。
  • gFOBT筛查 vs 不筛查:19.5年RR 0.91(95%CI 0.84-0.98),30年RR 0.78(95%CI 0.65-0.93)。
  • FIT检测癌症:敏感性0.74,特异性0.94;粪便DNA联合FIT:敏感性0.93,特异性0.85。
  • 结肠镜筛查严重危害:穿孔3.1/10 000例操作,大出血14.6/10 000例操作。

临床怎么用

  • 临床可根据证据水平、检测能力和危害风险选择结直肠癌筛查方案。
  • 乙状结肠镜、gFOBT、FIT和结肠镜筛查均与结直肠癌死亡率或发病率降低相关。
  • FIT和粪便DNA联合FIT检测癌症的敏感性高于高灵敏度gFOBT。
  • 结肠镜筛查需注意穿孔和大出血等严重危害。

局限性

  • CT结肠成像可能因低剂量电离辐射带来危害。
  • CT结肠成像检出结肠外发现的净获益或净危害尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Colorectal cancer (CRC) remains a significant cause of morbidity and mortality in the US. OBJECTIVE: To systematically review the effectiveness, test accuracy, and harms of screening for CRC to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed, and the Cochrane Central Register of Controlled Trials for relevant studies published from January 1, 2015, to December 4, 2019; surveillance through March 26, 2021. STUDY SELECTION: English-language studies conducted in asymptomatic populations at general risk of CRC. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently appraised the articles and extracted relevant study data from fair- or good-quality studies. Random-effects meta-analyses were conducted. MAIN OUTCOMES AND MEASURES: Colorectal cancer incidence and mortality, test accuracy in detecting cancers or adenomas, and serious adverse events. RESULTS: The review included 33 studies (n = 10 776 276) on the effectiveness of screening, 59 (n = 3 491 045) on the test performance of screening tests, and 131 (n = 26 987 366) on the harms of screening. In randomized clinical trials (4 trials, n = 458 002), intention to screen with 1- or 2-time flexible sigmoidoscopy vs no screening was associated with a decrease in CRC-specific mortality (incidence rate ratio, 0.74 [95% CI, 0.68-0.80]). Annual or biennial guaiac fecal occult blood test (gFOBT) vs no screening (5 trials, n = 419 966) was associated with a reduction of CRC-specific mortality after 2 to 9 rounds of screening (relative risk at 19.5 years, 0.91 [95% CI, 0.84-0.98]; relative risk at 30 years, 0.78 [95% CI, 0.65-0.93]). In observational studies, receipt of screening colonoscopy (2 studies, n = 436 927) or fecal immunochemical test (FIT) (1 study, n = 5.4 million) vs no screening was associated with lower risk of CRC incidence or mortality. Nine studies (n = 6497) evaluated the test accuracy of screening computed tomography (CT) colonography, 4 of which also reported the test accuracy of colonoscopy; pooled sensitivity to detect adenomas 6 mm or larger was similar between CT colonography with bowel prep (0.86) and colonoscopy (0.89). In pooled values, commonly evaluated FITs (14 studies, n = 45 403) (sensitivity, 0.74; specificity, 0.94) and stool DNA with FIT (4 studies, n = 12 424) (sensitivity, 0.93; specificity, 0.85) performed better than high-sensitivity gFOBT (2 studies, n = 3503) (sensitivity, 0.50-0.75; specificity, 0.96-0.98) to detect cancers. Serious harms of screening colonoscopy included perforations (3.1/10 000 procedures) and major bleeding (14.6/10 000 procedures). CT colonography may have harms resulting from low-dose ionizing radiation. It is unclear if detection of extracolonic findings on CT colonography is a net benefit or harm. CONCLUSIONS AND RELEVANCE: There are several options to screen for colorectal cancer, each with a different level of evidence demonstrating its ability to reduce cancer mortality, its ability to detect cancer or precursor lesions, and its risk of harms.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lin JS, Perdue LA, Henrikson NB, et al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021. PMID: 34003220. doi:10.1001/jama.2021.4417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。